Table 1.
Clinical outcome according to baseline characteristics.
Figure 1.
Clinical outcome according to cachexia and AKT1-rs1130233 polymorphism.
(A and B) Kaplan–Meier survival curves according to cachexia in the first and second cohort of patients. (C and D) Kaplan–Meier survival curves according to the AKT1-rs1130233 polymorphism in the first and second cohort of patients. p-values were calculated with the log-rank test. OS: Overall survival.
Table 2.
Correlation between cachexia and candidate SELP, AKT1 and IL-6 SNPs.
Table 3.
Clinical outcome according to candidate SELP, AKT1 and IL-6 SNPs.
Table 4.
Factors associated with overall survival in the multivariate analysis.
Figure 2.
Akt1 expression in muscle samples according to the AKT1-rs1130233 polymorphism.
Bar graphs illustrating the mean±SD expression of total Akt1 (A) and phospho-Akt1 (B) in muscle samples from patients with differential AKT1-rs1130233 genotypes (N = 9 samples in each group) *p<0.05.